Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

#RemoteDetailing

- PMLiVE

Researchers use AI to identify drugs that could be repurposed for Alzheimer’s

Eli Lilly's JAK inhibitor Olumiant identified as a potential treatment for repurposing

- PMLiVE

bluebird bio says AML case “very unlikely” to be related to gene therapy LentiGlobin

bluebird bio's gene therapy LentiGlobin is used to treat sickle cell disease

LUCID GROUP PARTNERS WITH NEW INVESTOR ICG

Lucid Group has secured a new investment from Intermediate Capital Group (ICG) to support its continued ambition to build a global business that delivers life transforming value for everyone.Founded in...

Lucid Group Communications Limited

- PMLiVE

Stakeholder meeting kick-starts dialogue on COVID-19 vaccine supply chain issues

Meeting discussed potential solutions to COVID-19 vaccine manufacturing bottlenecks

- PMLiVE

Pfizer/BioNTech could supply three billion doses of COVID-19 vaccine in 2022

J&J reportedly facing vaccine supply issues in the EU

- PMLiVE

Novartis’ canakinumab misses the mark in previously treated NSCLC

Drug failed to improve survival in previously-treated metastatic NSCLC patients

- PMLiVE

Charlotte Sale joins Page & Page and Partners as senior account director

Sale has worked for major pharma and dental manufacturers for over 14 years

- PMLiVE

Mapping the patient journey: eight ways to improve support programmes

Chris Ross examines how pharma can drive awareness and adoption of patient support solutions

- PMLiVE

Yescarta gains first FDA approval for indolent follicular lymphoma

First CAR-T cell therapy to be approved in this indication

- PMLiVE

WHITE PAPER: What’s missing in women’s health?

In July of last year, amidst stories in the press around HRT and contraception shortages, endometriosis going undiagnosed and unsafe medical devices being offered to women, we wrote an edition...

IGNIFI

- PMLiVE

Pfizer/BioNTech’s COVID-19 vaccine neutralises Brazil variant, suggests study

Neutralisation of variant 'roughly equivalent' to original SARS-CoV-2 strain

- PMLiVE

Lilly partners with Biolojic Design to develop diabetes antibody therapies

Agreement could be worth up to $121m in milestone payments

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links